shock wave therapy, platelet-rich plasma or pharmaceutical ...€¦ · •2006-2019 •11...

17
Shock wave therapy, platelet-rich plasma or pharmaceutical treatments? Johannes Tol

Upload: others

Post on 01-Feb-2021

1 views

Category:

Documents


0 download

TRANSCRIPT

  • Shock wave therapy, platelet-richplasma or pharmaceutical treatments?

    Johannes Tol

  • • 2006-2019

    • 11 single-arm case series

    • 1 prospective non-randomised cohort

    • 3 RCTs

    Liddle AD, Rodriguez-Merchan EC. Platelet-Rich Plasma in the Treatment of Patellar Tendinopathy: A Systematic Review. Am J Sp Med 2014

    .

    PRP in patellar Tendinopathy

  • • 2009 Kon et al. – FU 6 mnths–PRP group (n=20): 3 PRP injections→16/20 (80%) satisfied

    • 2012 Gosens et al. – FU 18.4 mnths–PRP group (n=36): 1 PRP injection–Significant improvement in VISA-P

    • 2014 Bellaiche et al. – FU 24 mnths–PRP group (n=28): 3 PRP injections→Significant improvement in VISA-P (39 to 94)

    Prospective case series

  • In my hands PRP works !!

  • • 2013 Vetrano et al. - AJSM– FU 2, 6, 12 m–PRP group (n=23), 2 injections leucocyte-rich–ESWT group (N=23)

    • PRP superior to ESWT (VISA-P):• at 6-months (86 ± 14. vs 74 ± 20;P = .014) • and 12-months (91 ± 10 vs 78 ± 20; P =.026)

    • Not superior at 2 months

    PRP vs Shock wave: Non-blinded RCT

  • • 2014 Dragoo et al. - AJSM– FU 2, 6 m

    –PRP group (n=10): 1 PRP injection leucocyte-rich

    –Dry needling group (N=13)

    • PRP NOT superior at 6-months

    • PRP superior at 2 months (87 ± 14 vs 74 ± 20;P = .014)

    RCT PRP vs Dry Needling: Non-blinded

  • • 2019 Scott et al. - AJSM– FU 3, 6, 12 m– LR-PRP group (n=19): 1 PRP injection leucocyte-rich + Rehab– LP-PRP (N=19): 1 PRP injection leucocyte-poor + Rehab–Saline (N=19) + Rehab

    • Clinical relevant effect of 13 on VISA-P at 12 weeks:- LR-PRP: 35% improved- LP-PRP: 72%- Saline: 71%

    RCT placebo controlled

  • Short-term (2m): no strong evidence to support the use of PRP

    Mid-term (6, 12 m): no evidence to support the use of PRP

    Best evidence synthesis PRP

  • • Until 2018

    • 6 prospective non-randomised cohort study

    • 5 RCTs

    ESWT in patellar Tendinopathy

  • ESWT in patellar Tendinopathy

  • Focused vs PLACEBO ESWT (VISA-P, VAS pain)

    2 RCTs

    Moderate level of evidence:

    No difference

  • Focused vs Conservative therapy (VISA-P, VAS pain)

    1 RCT (no blinding, 2-3 yrs FU)

    Conservative: NSAIDs+PT+knee strap+exercise

    Superior results for focused

  • Summary ESWT: Low level of evidence for ..

  • NSAIDs in patellar Tendinopathy

    Conflicting evidence

    Short-term positive effect (1 week)

  • No strong/moderate evidence

    to support the use of

    PRP injections

    ESWT

    NSAIDs

    Take home message